NOVEMBER 2023LIFE SCIENCES REVIEW9mitigating development risks wherever possible. We differentiate ourselves by not working with new molecules but enhancing existing ones like bupivacaine. This is achieved through liposomal encapsulation, extending its effectiveness significantly. Our twin objectives are clear: establishing cost efficiency that can compete across various markets--branded or generic--and setting ourselves apart distinctly. For instance, consider our ProbudorTM asset. Before acquisition, rigorous preclinical research was essential to prove its markedly superior and more durable effects compared to existing options in the market. This meticulous approach isn't limited to one asset--it's consistently applied to our entire portfolio. Every purchase we consider must showcase a strong potential for surpassing existing alternatives or offering remarkable differentiation. This comprehensive strategy guarantees that our portfolio matches our mission and delivers substantial value. How does your company's approach differ from the traditional methods in the marketplace today?While we might not be drastically different from other micro-companies or startups in the preclinical stage, there's a key factor that sets us apart. It's our remarkable ability to evaluate assets thanks to our exceptional team.Our team's diversity speaks volumes about our distinctiveness. We don't just assess products based on their novelty; we bring in medical experts to weigh in. With physicians on board, including directors specializing in anesthesia, pain management, and regulatory affairs, our evaluation goes beyond medical potential. We also delve into regulatory feasibility--can these products navigate the intricate FDA process? Consider Dr. Eric Floyd, who boasts an impressive track record of getting 30 to 40 products approved within the regulatory realm. Coupled with my experience and Gerald Bruce's insights, we focus on another crucial aspect: market access. Will insurance companies cover these products? In essence, our approach covers all bases. In this complex landscape, overlooking any dimension could prove detrimental. You might breeze through the approval process but stumble on reimbursement, or you might possess a groundbreaking molecule with an exceptional delivery mechanism yet face challenges with FDA approval. While success isn't guaranteed, our goal is to minimize risks. That's why every product we license undergoes a thorough assessment--considering clinical, regulatory, and market access facets. Could you offer insights into any ongoing projects you're currently engaged in? Specifically, what processes and technologies have you employed to ensure their success? A particularly intriguing focus has been our Molecular Envelope Technology (MET). While our liposomal technology is impressive, MET takes it even further. Leveraging intranasal delivery, we're revolutionizing the administration of orally taken products, channeling them directly to the brain--their intended destination. This bypasses the liver and the gastrointestinal route entirely. With no plasma involvement, everything now reaches the brain, highlighting substantial potential. MET enables us to transport molecules to the brain that wouldn't typically breach the blood-brain barrier on their own--such as our enkephalin asset. We are elevating the bioavailability of select products. For instance, consider our cannabidiol application. Our technology achieves equivalent brain delivery using only around one-third of the dosage required for an oral form. This approach effectively addresses issues associated with liver interactions, gastrointestinal disruptions, and plasma degradation. Our current focus revolves around these groundbreaking advancements. The significance of these products is emphasized by the backing of the National Institutes of Health (NIH). We've secured tangible grant opportunities and in-kind grants from the NIH, substantially propelling the early-stage progress of both our Molecular Envelope Technology and liposomal delivery platforms. The excitement isn't confined to our team--it's a clear testament to the monumental potential these innovations harbor. What advice would you like to give your colleagues and peers in the industry? When evaluating assets, maintaining authenticity is paramount for our company. We are resolute about bringing to market only what we genuinely believe in. Equally important is the composition of our team. We ensure that those surrounding us possess the necessary experience and expertise in the given area. If such individuals are lacking, we proactively seek them out. This step is not just important; it's critical. Our board of directors is a testament to this approach. It's a dynamic blend of expertise spanning finance, commercialization, medical, regulatory affairs, and academia, forming a comprehensive team. The emphasis on encompassing diverse knowledge and skills is pivotal. By creating this collaboration, authenticity naturally shines through, especially when we choose which molecules to pursue.
< Page 8 | Page 10 >